A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will l
| Condition(s) | Heart Failure |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks. |
| Who can participate | Inclusion Criteria: * Age 40-84 years (both inclusive) at the time of signing the informed consent. * Documented symptomatic heart failure (HF) diagnosed greater than or equal to (≥) 180 days prior to screening with at least weekly need for oral diuretic treatment, and New York Heart Association class II-III at screening. * Clinically stable and on optimized doses and unchanged drug classes of guideline-directed HF therapy ≥ 45 days prior to randomisation. * Left ventricular ejection fraction (LVEF) less than (\<) 50 percent (%) as assessed by echocardiography at screening, measured by central laboratory. * Left ventricular hypertrophy or left ventricular dilatation assessed by echocardiography at screening measured by central laboratory with any of the following: 1. LVMi greater than (\>) |
| Ages | 40 Years to 84 Years |
| Sex | All |
| Lead sponsor | Novo Nordisk A/S |
| Locations | Concord, New South Wales, Australia; Brisbane, Queensland, Australia; Adelaide, South Australia, Australia; Bedford Park, South Australia, Australia; Hobart, Tasmania, Australia; Clayton, Victoria, Australia (+86 more sites) |
| Start date | 2025-06-30 |
| NCT ID | NCT06979375 |
| Official listing | https://clinicaltrials.gov/study/NCT06979375 |